Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Hydroxyamphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.95 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamphetamine SCHEMBL219710 | 1.00 | TAAR1 (0.95) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL125440 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| (S)-P-Hydroxyamphetamine SCHEMBL256809 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL125442 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| (S)-P-Hydroxyamphetamine SCHEMBL9707065 | 0.95 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL221649 | 0.95 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL28160718 | 0.95 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL11539011 | 0.95 | TAAR1 (0.95) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL221291 | 0.95 | TAAR1 (0.95) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL221647 | 0.95 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | ELIXIR MEDICAL CORPORATION (US) | 2018-11-13 | — | — | US | claimed |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2017-05-04 | — | — | US | claimed |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2015-12-10 | — | — | US | claimed |
| US-20130230571-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2013-09-05 | — | — | US | claimed |
| EP-2624834-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | Elixir Medical Corporation (US) | 2013-08-14 | — | — | EP | claimed |
| EP-1480677-B8 | COMPOSITION FOR STABILIZING HYALURONIC ACID | CARL ZEISS MEDITEC SAS (FR) | 2012-05-23 | — | — | EP | claimed |
| WO-2012047813-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2012-04-12 | — | — | WO | claimed |
| EP-1480677-B1 | COMPOSITION FOR STABILIZING HYALURONIC ACID | IOLTECH (FR) | 2012-02-29 | — | — | EP | claimed |
| US-8088789-B2 | Administering hemiketal ring and seco-macrocyclic lactones; immunosuppressive, anti-proliferative, anti-fungal and anti-tumor | ELIXIR MEDICAL CORPORATION (US) | 2012-01-03 | — | — | US | claimed |
| EP-2352459-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | Elixir Medical Corporation (US) | 2011-08-10 | — | — | EP | claimed |
| EP-2254412-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | Elixir Medical Corporation (US) | 2010-12-01 | — | — | EP | claimed |
| US-20100086579-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2010-04-08 | — | — | US | claimed |
| WO-2010040064-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2010-04-08 | — | — | WO | claimed |
| WO-2009114010-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2009-09-17 | — | — | WO | claimed |
| US-20080234309-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2008-09-25 | — | — | US | claimed |
| EP-1480677-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | IOLTECH (FR) | 2004-12-01 | — | — | EP | claimed |
| US-20030133986-A1 | Compositions for stabilizing poly (carboxylic acids) | TSAO FU-PAO (US) | 2003-07-17 | — | — | US | claimed |
| WO-2003043660-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | claimed |
| US-12458532-B2 | Multi-dose ocular fluid delivery system | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-11-04 | — | — | US | disclosed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | CHRM2, CHRM1, CHRM5 | TAAR1 4388/4885SLC6A2 4682/4885SLC6A3 4136/4885 |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | TAAR1 3894/4885SLC6A2 3893/4885SLC6A3 3439/4885 |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | TAAR1 3837/4885SLC6A2 3901/4885SLC6A3 3482/4885 |
| US-20080234309-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | TAAR1 3894/4885SLC6A2 3893/4885SLC6A3 3439/4885 |
| US-20100086579-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | VIP, MIF, MYLK | TAAR1 4363/4885SLC6A2 4867/4885SLC6A3 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.